PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Desogestrel (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
30/03/2015
Paracetamol Infusionslösung (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
25/03/2015
Core Safety Profile Iohexol
PSUR-outcome
|
25/03/2015
Core Safety Profile Iodixanol
PSUR-outcome
|
25/03/2015
Finasterid 5mg (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
25/03/2015
Iloprost (EU PSUR Worksharing Summary Assessment Report)
PSUR-outcome
|
25/03/2015
Core Safety Profile Venlafaxin
PSUR-outcome
|
25/03/2015
Amiodaron zur intravenösen Verabreichung
PRAC signal recommendation
|
24/03/2015
Risiko für Syndrom der inadäquaten Sekretion des antidiuretischen Hormons (SIADH).
Nähere Informationen finden Sie auf der Website der EMA.
Valproat und verwandte Stoffe
PRAC signal recommendation
|
20/02/2015
Nähere Informationen finden Sie auf der Website der EMA.
Lithium
PRAC signal recommendation
|
20/02/2015
Risiko für solide renale Tumore.
Nähere Informationen finden Sie auf der Website der EMA.